MedPath

Early Detection of Coronary Artery Disease by Polygenic and Metabolic Risk Scoring

Not Applicable
Completed
Conditions
Coronary Artery Disease
Registration Number
NCT04604353
Lead Sponsor
Baker Heart and Diabetes Institute
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
1059
Inclusion Criteria

Inclusion Criteria:<br><br> 1. Asymptomatic subjects age 40-70y<br><br> 2. Statin naïve<br><br> 3. TC = 6.5 mmol/L and LDLC <5 mmol/L, and<br><br> 4. 5 year Australian risk =2%.<br><br>Exclusion Criteria:<br><br> 1. Symptomatic coronary, cerebrovascular, or peripheral vascular disease<br><br> 2. Intolerance of statins or currently on statins for any length of time<br><br> 3. Pre-existing muscle disease (eg polymyositis, fibromyalgia) - this may be confused<br> with myalgia from statins<br><br> 4. Patients on drugs that increase the risk of myopathy/rhabdomyolysis such as<br> cyclosporine and strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, and<br> HIV/hepatitis C protease inhibitors)<br><br> 5. Atrial fibrillation (interferes with CTCA)<br><br> 6. Chronic kidney disease on haemodialysis (because of vascular calcification) or GFR<br> <50ml/min per 1.73m2 using the Modification of Diet in Renal Disease (MDRD) formula<br><br> 7. Inability to provide informed consent<br><br> 8. Major systemic illness eg. malignancy; rheumatoid arthritis<br><br> 9. Women of child bearing potential (due to performance of CT)<br><br> 10. Poorly controlled hypertension: SBP> 200 and or DBP > 100<br><br> 11. Severe psychiatric disorder (eg bipolar depression; psychosis)<br><br> 12. Patients eligible for treatment based on current Australian guidelines (5 year risk<br> >15%)<br><br> 13. Patients eligible for treatment based on current PBS thresholds TC >7.5 mmol/l and<br> other criteria (see below).

Exclusion Criteria

Not provided

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Change in cardiovascular risk in each group
Secondary Outcome Measures
NameTimeMethod
Medication adherence in each group
© Copyright 2025. All Rights Reserved by MedPath